← All trials
NCT03220841
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2017
- Primary completion
- May 31, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of New South WalesLead sponsor
- AbbVieCollaborator
- University of New South WalesReponsible party - principal investigator
- University of New South WalesOverall official - principal investigator
- Australasian Gastro Intestinal Research Foundation (AGIRF)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.